A safety study of a B-class CpG ODN in Sprague–Dawley rats (pages 60–71)
Li Liu, Lianzhong Shen, Xiaomeng Liu, Yongli Yu, Yinzeng Li, Liying Wang, Chunyan He, Jianning Sun and Bo Li
Article first published online: 28 APR 2011 | DOI: 10.1002/jat.1683
To investigate the safety profile of a newly developed CpG ODN, CpG 684, we conducted a 28-day repeated dose toxicity study in rats. CpG 684 evaluated up-regulated the expressions of CD40 and CD86 molecules, induced cell hyperplasia in white pulp of spleen, and caused inflammatory cell infiltration and hyperplasia of fibrous tissue at injection sites. CpG 684 at 150 µg per rat increased the monocyte numbers and spleen weights, and led to the decrease in peripheral lymphocyte and some changes in serum chemistry.